Current economic conditions dominate business strategies. While healthcare has fared better than other industries, it will not be immune from the effects of the current recession. But what aspects of healthcare will be impacted? How much of spending will be out of the consumer's pocket? How will some novel trends (retail clinics, medical tourism) fit into this economy? It is commonly asserted that OTC and generic drugs sales will be boosted. Will this pan out? What will be the possible effects of various types of healthcare plans that might be implemented?
As part of its research, Kalorama has profiled and detailed the activities of several companies in the pharmaceutical, retail, healthcare financing and information technology fields that likely to play some role in the healthcare economy of 2009:
In Healthcare in a Recession,Kalorama Information has examined all of the key medical markets in the past and has witnessed change and in some sector's profits due to economic conditions. Kalorama has consulted its experts in key areas and asked about the effect of the recession. This report takes a broad look at the healthcare market in a recession from the many areas of healthcare that Specifically the report address:
- The State of the Pharmaceutical Industry
- Outsourcing and Offshoring
- Generic Drugs: A Coming Boom?
- Over the Counter Drugs
- Possible impact of Healthcare Legislation
- Out of Pocket Healthcare Spending: Current and Future
- The Retail Clinic Phenomenon
- Availability of Health Insurance
- Medical Tourism: Boom or Bust?
- Influential Pharmacists
As part of its research, Kalorama has profiled and detailed the activities of several companies in the pharmaceutical, retail, healthcare financing and information technology fields that likely to play some role in the healthcare economy of 2009:
- APFUSA
- Atlantic Care
- Aurora Quick Care
- Capitol One Healthcare Finance
- Care Credit
- Cerner Corporation
- Credit Medical
- CSI Financial Services
- E- Financing Solutions
- GlaxoSmithKline
- Hospira Inc.
- Med Basics
- McKesson Corporation
- Medco Health Solutions, Inc.
- Merck & Co. Inc
- Med choice Financial
- MedDirect
- Minute Clinic
- Novartis
- My Healthy Access
- Now Medical Centers
- PFS
- Quick Health
- Rediclinic
- Reliance Medical Finance
- Solantic
- Take Care Health Systems
- Target Clinic Medical Associates
- TEVA Pharmaceutical Industries, Ltd.
- Wyeth (Pfizer)
- Siemens Medical Solutions
- Wal - Mart
- CHAPTER ONE: EXECUTIVE SUMMARY
- Out of Pocket Spending
- Healthcare Legislation
- State of the Pharmaceutical Industry, 2009 • Meeting Investor Expectations • Erosion of Blockbuster Sales • Increased Generic Competition • Pricing Pressures • Pipeline Output Slowing Compared to ROI • Mergers &Aquisitions
- Retail Clinics
- OTC/Generic Drugs
- CHAPTER TWO: INTRODUCTION
- The U.S. Healthcare System Today
- Overview THE NEED FOR ALTERNATIVES
- High Cost of Care
- Healthcare Reform
- CHAPTER THREE: OUT-OF-POCKET EXPENDITURES: THE MARKET IN 2009
- Types of Expenditures
- Insurance Co-Payments
- Direct Payments
- Premiums and Plan Fees
- Cash or Check
- Credit Cards
- Loans and Lines of Credit
- Flexible Spending Accounts
- Health Savings Accounts
- Medical Financing
- Elective Procedures
- Non-Elective Procedures and Prescription Drugs Consumers Who Pay Out Of Pocket
- The Uninsured and Underinsured
- Medicaid Recipients
- The Disabled
- Senior Citizens
- The Mentally Ill
- The Obese
- Persons with Chronic Conditions
- CHAPTER FOUR: OUT-OF-POCKET EXPENDITURES: THE MARKET IN 2009 - 2013
- Out-of-pocket Expenditure Growth Drivers
- Payment Methods
- Consumers Who Pay Out-of-pocket
- CHAPTER FIVE: OVER THE COUNTER DRUGS: IN POSITION
- United States Market
- OTC and Recession: Avoiding the Copay
- Behind the Counter Drugs?
- CHAPTER SIX: INFLUENTIAL PHARMACISTS
- Markets - Pharmacists Impact
- The Prescribing Pharmacist
- Main Drivers For Increased Pharmacist Prescription Authority
- CHAPTER SEVEN: MEDICAL TOURISM: BOOM OR BUST?
- Motivations for Medical Tourism
- Impact of Recession
- True Medical Tourism vs. All Healthcare for Foreigners
- CHAPTER EIGHT: STATE OF THE PHARMACEUTICAL MARKET: OFFSHORING AND OUTSOURCING
- Meeting Investor Expectations
- Erosion of Blockbuster Sales
- Increased Generic Competition
- Pricing Pressures
- Pipeline Output Slowing Compared to ROI
- M&A Offshoring Clinical Trials
- Size and Growth of the Market
- Outsourcing: No Longer Optional For Pharma
- Strategic Outsourcing
- Outsourcing Manufacturing Operations
- CHAPTER NINE: GENERIC DRUGS: COMING BOOM?
- Overview
- Issues in Generics
- CHAPTER TEN: RETAIL CLINICS
- Retail Clinics Business
- Competition with Primary Care Providers
- Regulation
- CHAPTER ELEVEN: IMPACT OF HEALTHCARE LEGISLATION
- Overview
- Change for Pharma
- Focus on Cost - Cutting
- Healthcare Reform
- CHAPTER TWELVE: COMPANY PROFILES
- APFUSA
- Atlantic Care
- Aurora Quick Care
- Capitol One Healthcare Finance
- Care Credit
- Cerner Corporation
- Products and Service
- Key Competitors
- Credit Medical
- CSI Financial Services
- E- Financing Solutions
- GlaxoSmithKline
- History and Lines of Business
- Strategic Alliances
- Vaccine Products
- OTC Products
- Financial Information
- Hospira Inc.
- Med Basics
- McKesson Corporation
- Company Overview
- Products and Service
- Medco Health Solutions, Inc.
- Merck & Co. Inc
- History and Lines of Business
- Strategic Alliances
- Vaccine Products
- Financial Information
- Med choice Financial
- MedDirect
- Minute Clinic
- Novartis
- History and Lines of Business
- Strategic Alliances
- Vaccine Products
- My Healthy Access
- Now Medical Centers
- Pfs
- Quick Health
- Rediclinic
- Reliance Medical Finance
- Solantic
- Take Care Health Systems
- Target Clinic Medical Associates
- TEVA Pharmaceutical Industries, Ltd.
- Wyeth (Pfizer)
- History and Lines of Business
- Vaccine Products
- OTC Products
- Financial Information
- Siemens Medical Solutions
- Key Competitors
- Growth Strategy
- Locations
- Wal - Mart
- LIST OF EXHIBITS
- CHAPTER TWO: INTRODUCTION
- Figure 2-1:National Health Expenditures (NHE) and NHE as a Percent of GDP, 1980 - 2013
- Figure 2-2: Unnecessary Deaths Resulting From Variations in Health Care Quality, by Condition (Prenatal Care, Diabetes Care, Beta Blocker Treatment, Breast Cancer Screening, Cholesterol Management, High Blood Pressure, Diabetes)
- Figure 2-3:HEDIS Scores by Quality of Health Care Plan, 2008
- Table 2-1: U.S. Health Care Coverage by State, 2008
- CHAPTER THREE: OUT-OF-POCKET EXPENDITURES THE MARKET IN 2009
- Figure 3-1:Premium Increases vs. Increases in Workers Earnings and Prices, 1989 - 2008
- Figure 3-2: Consumer Out-of-pocket Health Care Expenditures,
- Figure 3-3:Consumer Out-of-pocket Health Care Expenditures by Payment Type,2008
- Table 3-1: Credit Card Debt of Consumers With Medical Debt, 2007
- Table 3-2: Credit Card Debt of Consumers With Medical Debt, 2007
- Table 3-3: Main Business Activities of Selected Medical Financing Companies,
- Figure 3-4:by Percentile of Total Health Spending,
- Figure 3-5:Methods of Financing Elective Procedures,
- Figure 3-6: Average Share Paid Out-of-pocket by U.S. Residents with Health Care Spending by Type of Service, 2008
- Figure 3-7: by Percentile of Total Health Spending and Type of Service, 2008
- Figure 3-8: Distribution of Out-of-pocket Spending on Non-Elective Procedures for the Average Person, 2008
- Figure 3-9: Distribution of Out-of-pocket Spending for the Average Person, by Spending Level, 2008
- Figure 3-10: Drug Cost Coverage by Payor Type (Public, Private, Cash) 1965, 1986, 2000, 2004, 2008
- Table 3-4: Obesity in the United States, 1980 - 2013
- Figure 3-11: Proportion of Adults Under Age 65 With Chronic Conditions, 2008
- CHAPTER FOUR: FORECASTED OUT-OF-POCKET EXPENDITURES: THE MARKET IN 2009 - 2013
- Table 4-1: Selected Rx-to-OTC Switches in the United States, 1990 - Present
- Table 4-2: Rx-to-OTC Switch Candidates in the United States, 2009 - 2013
- Table 4-3: Consumer Out-of-pocket Expenditures per Worker 2003-2013 (in $)
- Table 4-4: Consumer Out-of-pocket Expenditures by Type, 2003-2013
- Figure 4-1: Proportion of Consumer Out-of-pocket Spending by Type of Health Care Expenditure
- Table 4-5: Consumer Out-of-pocket Expenditures by Type, 2001-2011
- Figure 4-2: Proportion of Consumer Out-of-pocket Spending by Payment Type, 2003, 2008, 2013
- Table 4-6: Amount of Consumer Out-of-pocket Expenditures for Elective Procedures That Are Financed, 2003-2013
- Table 4-7: Amount of Consumer Out-of-pocket Expenditures for Non-Elective Procedures That Are Financed, 2001-2011
- Figure 4-3: Proportion of Consumer Out-of-pocket Spending for Elective ProceduresThat is Financed (All Methods),
- Figure 4-4: Distribution of Out-of-pocket Spending on Non-Elective Procedures for the Average Person, 2008, 2013
- Figure 4-5: Proportion of Consumer Out-of-pocket Spending for Non-Elective Procedures That is Financed (All Methods),2008 - 2013
- Table 4-8: Size of High Risk Groups for High Out-of-pocket Health Care Expenditures, 2003-2013 (Millions of Persons)
- CHAPTER FIVE: OVER THE COUNTER DRUGS: IN POSITION
- Table 5-1: Projected US OTC Revenues 2008-2012
- CHAPTER SIX: INFLUENTIAL PHARMACISTS
- Figure 6-1: Declining Drug Purchases Not Influenced By Pharmacists, 2006-2012
- Table 6-1: Pharmacists Influence in Drug Selection and/or Therapy Aspect: 2007 and 2012
- Table 6-2: States Likely to Implement Independent Prescribing First
- CHAPTER SEVEN: MEDICAL TOURISM: BOOM OR BUST?
- Table 7-1: Cost Savings From Medical Tourism For Various Procedures, 2008
- Figure 7-1: US ’True Medical Tourism’ Revenues, 2008, 2010
- CHAPTER EIGHT: STATE OF THE PHARMACEUTICAL MARKET,: OFFSHORING AND OUTSOURCING
- Table 8-1: Clinical Trial Market in Select Countries 2006-2012
- Table 8-2: Global Prescription Pharmaceutical Contract Manufacturing Market Primary, Secondary and Biomanufacturing 2003-2013
- CHAPTER NINE: GENERIC DRUGS: COMING BOOM?
- Table 9-1: US Generic Drug Market 2008-2012
- CHAPTER TEN: RETAIL CLINICS
- Figure 10-1: Growth of U.S. Retail Clinic Services
- CHAPTER ELEVEN: IMPACT OF HEALTHCARE LEGISLATION
- Table 11-1: Likely Impact of Events and Proposed Legislation (Propsed Change, Probability, Positive Impact, Negative Impact)
- CHAPTER TWELVE: COMPANY PROFILES
Other selected research from the 'Business Development' category:
Partneringdesk H. Lundbeck A/S and Company Deals Briefing
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies. Learn More
Partneringdesk Allergan, Inc. and Company Deals Briefing
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies. Learn More
Other selected research from the 'Diagnostics' category:
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Trends in oncology partnering deals and oncology partnering agreement structures. Contains over 900 links to oncology partnering contract documents, reveals the top oncology deals by value and the most active oncology dealmakers. Learn More
Who is Who in Clinical Diagnostics in China (Manufacturers and Distributors Profiles, Market, Industry Overview )
Who is Who in Clinical Diagnostics in China, produced jointly with the firm McEvoy & Farmer, is the product of on-the-ground primary research on Chinese labs conducted in... Learn More
Other selected research from the 'Drugs' category:
The Global OTC Pharmaceutical Market 2009-2024
OTC pharma is influenced by changes in consumer spending - but significant commercial opportunities for OTC switching will drive market expansion worldwide. Learn More
Lung Cancer Drug Pipeline Update 2012
BioSeeker Group have identified 333 companies plus partners who are today developing 426 lung cancer drugs in 507 developmental projects in cancer across 243 different targets. In addition, there are 9 suspended drugs and another 189 drugs where development has been ceased. Learn More